ERBB2 and breast cancer: Given the immense therapeutic benefits that the existence of markers would bring to distinguishing the most aggressive tumors and differentiating between responders and non-responders to a specific therapy, we attempt to identify potential biomarkers associated with prognosis and response to Tz in HER2+ BC.